Brain shrinkage associated with Alzheimer’s immunotherapies may show effectiveness rather than harm

A loss of brain volume associated with new immunotherapies for Alzheimer’s disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a study led by UCL researchers.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup